| Kelly Theresia Dassow, FNP | |
|
4100 State Highway 66, Stevens Point, WI 54482-8410 | |
| (715) 997-6000 | |
| Not Available |
| Full Name | Kelly Theresia Dassow |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 4100 State Highway 66, Stevens Point, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184359499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 13193 (Wisconsin) | Primary |
| Entity Name | Marshfield Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Beaver Dam Community Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972188555 PECOS PAC ID: 2567370539 Enrollment ID: O20040210000666 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20040519001426 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700963048 PECOS PAC ID: 9032029871 Enrollment ID: O20070828000478 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20110526000807 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Lakeview Medical Center Inc Of Rice Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093201832 PECOS PAC ID: 6103737820 Enrollment ID: O20180817001484 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952890873 PECOS PAC ID: 5698071173 Enrollment ID: O20180904002962 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194317966 PECOS PAC ID: 9032029871 Enrollment ID: O20210409000059 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Theresia Dassow, FNP 1000 N Oak Ave, Marshfield, WI 54449-5703 Ph: (715) 387-5511 | Kelly Theresia Dassow, FNP 4100 State Highway 66, Stevens Point, WI 54482-8410 Ph: (715) 997-6000 |
News Archive
The viscoelasticity of natural and artificial biomaterials can be suitable for human physiological function by matching stress relaxation and creep properties.
Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When you decide to get on the river – in a kayak, canoe or paddle board, in summer or winter – you may have one goal, such as physical exercise or relaxation. But being open to various outcomes actually leads to a more fulfilling experience, says a Baylor University outdoor adventure expert.
› Verified 9 days ago
Mr. Ronald Glen Baker, APNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 910 Fremont St, Uwsp Health Service, Stevens Point, WI 54481 Phone: 715-346-4317 Fax: 715-346-4752 | |
Stephani Placek, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3233a Business Park Dr Ste 203, Stevens Point, WI 54482 Phone: 715-344-4541 | |
Karen M Hugill, APNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 900 Illinois Ave, Stevens Point, WI 54481 Phone: 715-346-5000 | |
Jodi L Strong, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 824 Illinois Ave, Stevens Point, WI 54481 Phone: 715-342-7500 | |
Julie A Hennes, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3301 Stanley St, Stevens Point, WI 54481 Phone: 715-341-7332 | |
Rebecca Jorgensen, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5409 Vern Holmes Dr, Stevens Point, WI 54482 Phone: 715-344-1600 | |
Mrs. Stephanie K Mundt, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5412 Us Highway 10 E, Stevens Point, WI 54482 Phone: 715-346-5243 Fax: 715-346-5419 |